Previous Article | Next Article ![]()
J Virol, March 1998, p. 2538-2540, Vol. 72, No. 3
Centro de Biología Molecular,
CSIC-UAM, Universidad Autónoma de Madrid, 28049 Madrid, Spain
Received 29 September 1997/Accepted 8 December 1997
The role of nitric oxide after poliovirus infection of the human
HeLa (carcinoma) and U937 (promonocytic) cell lines has been analyzed.
Both types of cells produced detectable levels of nitric oxide after
poliovirus infection. However, this production was not sufficient to
limit viral productivity. On the other hand, pretreatment with the
nitric oxide donor glycerine trinitrate lengthened the course of
poliovirus infection.
It has been demonstrated that nitric
oxide (NO) plays an important role in defense against a wide spectrum
of microbial pathogens (22). Nevertheless, the antiviral
activity of NO has not been observed until recently (6, 10).
In those first reports, murine macrophages produced NO after activation
with gamma interferon and resisted infection with herpes simplex virus
type 1 (HSV-1) (6), vaccinia virus, or ectromelia virus
(10). Further reports pointed to NO as a first line of
defense against infections in murine systems with RNA viruses (e.g.,
vesicular stomatitis virus [4, 12], Friend leukemia
virus [3], encephalomyocarditis virus
[8]; Sindbis virus [SV] [25], or
Japanese encephalitis virus [15]) and DNA viruses,
such as HSV-1 (6) or vaccinia virus (9, 24).
Nevertheless, in some cases the effect of the production of NO in
cultured cells is difficult to extrapolate to animals systems (14,
23).
As regards human cells, the role of NO after viral infection remains to
be unveiled. NO produced by human B cells seemed to inhibit
Epstein-Barr virus reactivation (20). Moreover, NO donors can inhibit human immunodeficiency virus type 1 (HIV-1) replication in
human peripheral blood mononuclear cells (5). Nevertheless, Koka et al. (11) suggest that some pathologic effects that
appeared in the central nervous system after HIV-1 infection could be
due to the toxic effect of NO. NO constitutively produced by activated human promonocytic U937 cells plays a role in resistance to H-1 autonomous parvovirus infection (17). Infection with HSV-1
of U937 cells differentiated with the phorbol ester 12-myristate 13-acetate induced the production of significant levels of NO; however,
this NO production did not change viral production (16).
Despite the protective effect of NO against certain viral infections, a
number of recent studies indicate a harmful role of NO in many systems.
Thus, NO seems to play an important role in the development of
pneumonia triggered by influenza virus in mice (2) and in
pathogenesis in mice infected with the tick-borne encephalitis
flavivirus (13). Furthermore, it has been reported that
infection of mice with coxsackievirus B3 (CVB3) induced NO in the
heart, aggravating the course of the viral myocarditis (21).
These results are in conflict with those of Lowenstein et al.
(19), who observed that NO ameliorated the effect of CVB3
infection in mice. In a recent work, Adler et al. (1) showed
that HSV-1-induced pneumonia in mice could be suppressed by the
inhibitor of inducible nitric oxide synthase (iNOS),
N We have studied the effect of NO on poliovirus infection. To this end,
human promonocytic U937 cells were cultured in RPMI 1640 (Life
Technologies, Paisley, United Kingdom) and supplemented with 10%
heat-inactivated fetal calf serum. HeLa cells were cultured in
Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum. Poliovirus type 1 (Mahoney strain) was propagated in HeLa
cells. Initially, the accumulation of NO in both human cell cultures
after addition of the NO donor glycerin trinitrate (GTN) (Merck,
Darmstadt, Germany) was studied. Fig. 1A
shows dose-dependent levels of NO, which increased during the course of
incubation, detected in both HeLa and U937 cells. For further assays,
cells were preincubated with 4 mg of GTN/ml for 12 h, since higher
concentrations produced cytotoxicity, as observed by trypan blue
staining (data not shown). In order to study the poliovirus-induced NO,
HeLa and U937 cells were infected at multiplicities of infection (MOI) of 0.5 and 5 PFU/cell, respectively. The formation of NO was measured as described by Green et al. (7). In each individual
experiment, aliquots of U937 or HeLa supernatants (0.1 ml), uninfected
or infected with poliovirus, were incubated, in triplicate, in
flat-bottom 96-well culture plates and mixed with the same amount of
Greiss reagent (0.1% naphthyl-ethylenediamine dihydrochloride
[Sigma] in distilled water and 1% sulfanilamide [Sigma] in 5%
phosphoric acid [vol/vol]). Subsequently, this mixture was incubated
for 10 min at room temperature and the optical density at 550 nm was measured in an MR 5000 microplate reader (Dynatech, Billingshurst, West
Sussex, United Kingdom). As illustrated in Fig. 1B, the infection induced a slight but significant production of NO. Incubation with 2 mM
L-NMMA (Calbiochem-Novabiochem Corporation, San Diego, Calif.) decreased the production of NO induced by the viral infection (Fig. 1B). Addition of monomethyl-D-arginine (Calbiochem)
as a control of specificity did not exert any effect on the
accumulation of NO (data not shown). Furthermore, infection of
GTN-pretreated cells did not modify the levels of NO produced with GTN
alone, suggesting that maximal levels of NO had been reached or that exogenous NO addition could inhibit cellular iNOS.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Effect of Nitric Oxide on Poliovirus Infection of
Two Human Cell Lines
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
-monomethyl-L-arginine
(L-NMMA). Considering all these controversial results, the
question of whether NO acts as an inhibitor of viral replication or as
a harmful agent remains unanswered.

View larger version (30K):
[in a new window]
FIG. 1.
Poliovirus induces NO production in human cells. (A)
Treatment of HeLa and U937 cell cultures with GTN produces NO
accumulation. Cells (105 per ml) were incubated at 37°C
in the presence or absence of the NO donor. At the indicated times, NO
production was assayed as detailed in the text. (B) HeLa or U937 cells
(105) were infected with poliovirus at MOIs of 0.5 and 5 PFU/cell, respectively. Subsequently, cultures were incubated at 37°C
in the presence or absence of 4 mg of GTN/ml. In parallel, cultures
were preincubated for 4 h with 2 mM L-NMMA (striped
bars). At 20 h p.i. the accumulation of NO was assayed. Values are
means ± standard deviations of three experiments, performed in
triplicate.
The implication of this endogenous NO production in HeLa and U937 cells after poliovirus infection is shown in Table 1. Treatment of the cultures with 2 mM L-NMMA altered neither the production of infectious poliovirus particles nor the cellular death observed by plaque assay and cell counting, respectively. On the other hand, and in agreement with previous findings (12), exogenous NO supplied by 12 h of pretreatment with 4 mg of GTN/ml produced an increase of cell viability and a 3.9- or 15-fold decrease in the PFU produced in HeLa and U937 cells, respectively, analyzed by means of a plaque assay performed on HeLa cell monolayers. This reduction of infectious particles was not due to a direct inhibitory effect of GTN on poliovirus input, since pretreatment of 5 × 106 poliovirus particles with 16 mg of GTN/ml for 5 h did not alter the subsequent infectivity of the virus (data not shown). Altogether, these results indicate that the addition of NO decreases poliovirus infection in both the HeLa and U937 human cell lines. However, the low level of endogenous NO production induced after the infection does not seem to be sufficient to alter the course of poliovirus infection. Morphological studies confirmed these results (data not shown).
|
We further studied the effect exerted by NO on the course of protein synthesis during poliovirus infection by polyacrylamide gel electrophoretic assay. In vivo labeling of newly synthesized proteins was carried out by giving 1-h pulses with 20 µCi of L-(35S) Pro-mix (approximately 70% L-[35S]methionine [>1,000 Ci/mmol] and 30% L-[35S]cysteine; Amersham Life Science, Little Chalfont, Buckinghamshire, United Kingdom)/ml in methionine- and cysteine-free medium. At 4 h postinfection (p.i.), some viral proteins could be detected in infected HeLa cells (MOI, 5). The inhibition of the cellular protein was more evident at later times after infection. This shutoff was almost total at 10 h p.i. (Fig. 2). Preincubation with 4 mg of GTN/ml delayed the induction of this shutoff. Cellular protein synthesis was detected even at 10 h p.i. Cells incubated for longer times after infection underwent total cellular destruction in all cultures (data not shown). In the case of the U937 cell line, previous work from our laboratory demonstrated a weaker effect of poliovirus, and a longer time of infection was necessary to achieve cellular destruction (18). Moreover, this cellular death was not followed by detectable levels of viral protein synthesis. Figure 2 confirms this weaker induction of shutoff after infection for U937 cells. However, even under these conditions, preincubation with GTN protected the cells. Altogether, these results show the protection afforded by NO against poliovirus infection.
|
These results represent the first indication of poliovirus-mediated NO production. Nevertheless, the level of NO detected did not seem to be sufficient to ameliorate the cytopathic effect produced by the virus. Activation of iNOS after picornavirus infection has been described only for murine systems, and the role of this endogenously produced NO remains unclear (8, 19, 21, 23). Thus, murine L-929 cells produced NO after encephalomyocarditis virus infection without counteracting viral replication (8). Another picornavirus, the cardiovirus of Theiler's murine encephalomyelitis, is an important model of virus-induced demyelinating disease. Although infection of the susceptible SJL strain of mice with Theiler's murine encephalomyelitis virus increased expression of iNOS, NO did not play a direct role in the late phase of demyelination (23). Furthermore, two independent groups have shown iNOS induction in the hearts of mice infected with the enterovirus CVB3 (19, 21). However, Mikami et al. (21) could not determine whether NO plays a cytotoxic or a cytoprotective role in the pathogenic mechanisms of myocardial dysfunction.
The infection of U937 cells by poliovirus described herein produced detectable levels of NO without the need of previous cellular activation. This finding contrasts with a previous study in which commitment to a more mature state of U937 cells was needed for the production of NO after infection by HSV-1 (16). This might suggest different pathways of iNOS induction triggered by virus infection. The role of this NO produced in vitro remains unknown. Further investigation should tackle the questions of whether infection of primary human cultures leads to the activation of iNOS and what role, if any, NO plays in an in vivo context. Regarding this point, Tucker et al. (25) suggest that NO could protect some types of cells against viral infection just until the specific immune response controls the infection.
In conclusion, it is clear from the present study that NO can delay poliovirus infection and that this picornavirus induces detectable production of NO, although probably not in sufficient amounts for the establishment of an antiviral state, at least in these culture systems.
| |
ACKNOWLEDGMENTS |
|---|
We are indebted to M. A. Alonso for critical reading of the manuscript.
Financial support was provided by the Plan Nacional (project no. BIO 94-0148) and by an Institutional Grant to the Centro de Biología Molecular by the Fundación Ramón Areces.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Centro de Biología Molecular, Universidad Autónoma de Madrid, 28049 Madrid, Spain. Phone: 34-1-397-5074. Fax: 34-1-397-4799. E-mail: JALOPEZ{at}TRASTO.CBM.UAM.ES.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Adler, H.,
J. L. Beland,
N. C. Del-Pan,
L. Kobzik,
J. P. Brewer,
T. R. Martin, and I. J. Rimm.
1997.
Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2).
J. Exp. Med.
185:1533-1540 |
| 2. |
Akaike, T.,
Y. Noguchi,
S. Ijiri,
K. Setoguchi,
M. Suga,
Y. M. Zheng,
B. Dietzschold, and H. Maeda.
1996.
Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals.
Proc. Natl. Acad. Sci. USA
93:2448-2453 |
| 3. | Akarid, K., M. Sinet, B. Desforges, and M. A. Gougerot-Pocidalo. 1995. Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. J. Virol. 69:7001-7005[Abstract]. |
| 4. | Bi, Z., and C. S. Reiss. 1995. Inhibition of vesicular stomatitis virus infection by nitric oxide. J. Virol. 69:2208-2213[Abstract]. |
| 5. |
Bukrinsky, M. I.,
H. S. Nottet,
H. Schmidtmayerova,
L. Dubrovsky,
C. R. Flanagan,
M. E. Mullins,
S. A. Lipton, and H. E. Gendelman.
1995.
Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease.
J. Exp. Med.
181:735-745 |
| 6. | Croen, K. D. 1993. Evidence for an antiviral effect of nitric oxide: inhibition of herpes simplex virus type 1 replication. J. Clin. Invest. 91:2446-2452. |
| 7. | Green, L. C., D. A. Wagner, J. Glogowsky, P. L. Skipper, J. S. Wishnok, and J. S. Tannenbaum. 1982. Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. Anal. Biochem. 126:131-136[Medline]. |
| 8. | Guillemard, E., M. Geniteau-Legendre, R. Kergot, G. Lemaire, J. F. Petit, C. Labarre, and A. M. Quero. 1996. Activity of nitric oxide-generating compounds against encephalomyocarditis virus. Antimicrob. Agents Chemother. 40:1057-1059[Abstract]. |
| 9. | Harris, N., R. M. L. Buller, and G. Karupiah. 1995. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69:910-915[Abstract]. |
| 10. |
Karupiah, G.,
Q. W. Xie,
R. M. L. Buller,
C. Nathan,
C. Duarte, and J. D. MacMicking.
1993.
Inhibition of viral replication by interferon- -induced nitric oxide synthase.
Science (Washington, D.C.)
261:1445-1448 |
| 11. |
Koka, P.,
K. He,
J. A. Zack,
S. Kitchen,
W. Peacock,
I. Fried,
T. Tran,
S. S. Yashar, and J. E. Merrill.
1995.
Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor , and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain.
J. Exp. Med.
182:941-952 |
| 12. |
Komatsu, T.,
Z. Bi, and C. S. Reiss.
1996.
Interferon- -induced type I nitric oxide synthase activity inhibits viral replication in neurons.
J. Neuroimmunol.
68:101-108[Medline].
|
| 13. | Kreil, T. R., and M. M. Eibl. 1996. Nitric oxide and viral infection: NO antiviral activity against a flavivirus in vitro, and evidence for contribution to pathogenesis in experimental infection in vivo. Virology 219:304-306[Medline]. |
| 14. | Lane, T. E., A. D. Paoletti, and M. J. Buchmeier. 1997. Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus. J. Virol. 71:2202-2210[Abstract]. |
| 15. | Lin, Y.-L., Y.-L. Huang, S.-H. Ma, C.-T. Yeh, S.-Y. Chiou, L.-K. Chen, and C.-L. Liao. 1997. Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J. Virol. 71:5227-5235[Abstract]. |
| 16. | López-Guerrero, J. A., and M. A. Alonso. 1997. Nitric oxide production induced by herpes simplex virus type 1 does not alter the course of the infection in human monocytic cells. J. Gen. Virol. 78:1977-1980[Abstract]. |
| 17. |
López-Guerrero, J. A.,
B. Rayet,
M. Tuynder,
J. Rommelaere, and C. Dinsart.
1997.
Constitutive activation of U937 promonocytic cell clones selected for their resistance to parvovirus H-1 infection.
Blood
89:1642-1653 |
| 18. | López-Guerrero, J. A., L. Carrasco, F. Martínez-Abarca, M. Fresno, and M. A. Alonso. 1989. Restriction of poliovirus RNA translation in a human monocytic cell line. Eur. J. Biochem. 186:577-582[Medline]. |
| 19. | Lowenstein, C. J., S. L. Hill, A. Lafond-Walker, J. Wu, G. Allen, M. Landavere, N. R. Rose, and A. Herskowitz. 1996. Nitric oxide inhibits viral replication in murine myocarditis. J. Clin. Invest 97:1837-1843[Medline]. |
| 20. | Mannick, J. B., K. Asano, K. Izumi, E. Kieff, and J. S. Stamler. 1994. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79:1137-1146[Medline]. |
| 21. | Mikami, S., S. Kawashima, K. Kanazawa, K. Hirata, Y. Katayama, H. Hotta, Y. Hayashi, H. Ito, and M. Yokoyama. 1996. Expression of nitric oxide synthase in a murine model of viral myocarditis induced by coxsackievirus B3. Biochem. Biophys. Res. Commun. 220:983-989[Medline]. |
| 22. | Nathan, C., and Q. W. Xie. 1994. Nitric oxide synthases: roles, tolls and control. Cell 78:915-918[Medline]. |
| 23. | Oleszak, E. L., C. D. Katsetos, J. Kuzmak, and A. Varadhachary. 1997. Inducible nitric oxide synthase in Theiler's murine encephalomyelitis virus infection. J. Virol. 71:3228-3235[Abstract]. |
| 24. | Rolph, M. S., W. B. Cowden, C. J. Medveczky, and I. A. Ramshaw. 1996. A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo. J. Virol. 70:7678-7685[Abstract]. |
| 25. | Tucker, P. C., D. E. Griffin, S. Choi, N. Bui, and S. Wesselingh. 1996. Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis. J. Virol. 70:3972-3977[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»